Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression

Chad A. Dickey, Peter Ash, Natalia Klosak, Wing C. Lee, Leonard Petrucelli, Michael Hutton, Christopher B. Eckman

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The microtubule-associated protein tau (MAPT) is a pathological component of several neurodegenerative diseases and clinical dementias. Here, we have investigated the effects of a series of commercially available FDA-approved compounds and natural products on total tau protein levels using a cell-based approach that allows for the rapid and efficient measurement of changes in protein expression. Results: The compounds that reduced tau largely fell within 3 functional categories with the largest percentage being microtubule regulators. Several of these candidates were validated in both a human neuroglioma and a human neuroblastoma cell line. While these drugs lead to a rapid reduction in tau protein levels, a selective decrease in MAPT mRNA expression was also observed. Conclusion: These findings suggest that the identified compounds that reduce tau levels may act either through direct effects on the MAPT promoter itself or by altering a feedback transcriptional mechanism regulating MAPT transcription. This is particularly interesting in light of recent evidence suggesting that MAPT 5' UTR mutations in late-onset PD and PSP cases alter the expression of tau mRNA. In fact, one of the compounds we identified, rotenone, has been used extensively to model PD in rodents. These observations may provide key insights into the mechanism of tau turnover within the neuron while also providing the first evidence that selectively reducing tau protein levels may be possible using compounds that are PDA-approved for other uses.

Original languageEnglish (US)
Article number6
JournalMolecular Neurodegeneration
Volume1
Issue number1
DOIs
StatePublished - 2006

Fingerprint

Microtubule-Associated Proteins
Microtubules
tau Proteins
Rotenone
Messenger RNA
5' Untranslated Regions
Biological Products
Neuroblastoma
Neurodegenerative Diseases
Dementia
Rodentia
Neurons
Cell Line
Mutation
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Clinical Neurology
  • Molecular Biology

Cite this

Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. / Dickey, Chad A.; Ash, Peter; Klosak, Natalia; Lee, Wing C.; Petrucelli, Leonard; Hutton, Michael; Eckman, Christopher B.

In: Molecular Neurodegeneration, Vol. 1, No. 1, 6, 2006.

Research output: Contribution to journalArticle

Dickey, Chad A. ; Ash, Peter ; Klosak, Natalia ; Lee, Wing C. ; Petrucelli, Leonard ; Hutton, Michael ; Eckman, Christopher B. / Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. In: Molecular Neurodegeneration. 2006 ; Vol. 1, No. 1.
@article{fd57b83ef25c46db964ed2a5013930a9,
title = "Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression",
abstract = "The microtubule-associated protein tau (MAPT) is a pathological component of several neurodegenerative diseases and clinical dementias. Here, we have investigated the effects of a series of commercially available FDA-approved compounds and natural products on total tau protein levels using a cell-based approach that allows for the rapid and efficient measurement of changes in protein expression. Results: The compounds that reduced tau largely fell within 3 functional categories with the largest percentage being microtubule regulators. Several of these candidates were validated in both a human neuroglioma and a human neuroblastoma cell line. While these drugs lead to a rapid reduction in tau protein levels, a selective decrease in MAPT mRNA expression was also observed. Conclusion: These findings suggest that the identified compounds that reduce tau levels may act either through direct effects on the MAPT promoter itself or by altering a feedback transcriptional mechanism regulating MAPT transcription. This is particularly interesting in light of recent evidence suggesting that MAPT 5' UTR mutations in late-onset PD and PSP cases alter the expression of tau mRNA. In fact, one of the compounds we identified, rotenone, has been used extensively to model PD in rodents. These observations may provide key insights into the mechanism of tau turnover within the neuron while also providing the first evidence that selectively reducing tau protein levels may be possible using compounds that are PDA-approved for other uses.",
author = "Dickey, {Chad A.} and Peter Ash and Natalia Klosak and Lee, {Wing C.} and Leonard Petrucelli and Michael Hutton and Eckman, {Christopher B.}",
year = "2006",
doi = "10.1186/1750-1326-1-6",
language = "English (US)",
volume = "1",
journal = "Molecular Neurodegeneration",
issn = "1750-1326",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression

AU - Dickey, Chad A.

AU - Ash, Peter

AU - Klosak, Natalia

AU - Lee, Wing C.

AU - Petrucelli, Leonard

AU - Hutton, Michael

AU - Eckman, Christopher B.

PY - 2006

Y1 - 2006

N2 - The microtubule-associated protein tau (MAPT) is a pathological component of several neurodegenerative diseases and clinical dementias. Here, we have investigated the effects of a series of commercially available FDA-approved compounds and natural products on total tau protein levels using a cell-based approach that allows for the rapid and efficient measurement of changes in protein expression. Results: The compounds that reduced tau largely fell within 3 functional categories with the largest percentage being microtubule regulators. Several of these candidates were validated in both a human neuroglioma and a human neuroblastoma cell line. While these drugs lead to a rapid reduction in tau protein levels, a selective decrease in MAPT mRNA expression was also observed. Conclusion: These findings suggest that the identified compounds that reduce tau levels may act either through direct effects on the MAPT promoter itself or by altering a feedback transcriptional mechanism regulating MAPT transcription. This is particularly interesting in light of recent evidence suggesting that MAPT 5' UTR mutations in late-onset PD and PSP cases alter the expression of tau mRNA. In fact, one of the compounds we identified, rotenone, has been used extensively to model PD in rodents. These observations may provide key insights into the mechanism of tau turnover within the neuron while also providing the first evidence that selectively reducing tau protein levels may be possible using compounds that are PDA-approved for other uses.

AB - The microtubule-associated protein tau (MAPT) is a pathological component of several neurodegenerative diseases and clinical dementias. Here, we have investigated the effects of a series of commercially available FDA-approved compounds and natural products on total tau protein levels using a cell-based approach that allows for the rapid and efficient measurement of changes in protein expression. Results: The compounds that reduced tau largely fell within 3 functional categories with the largest percentage being microtubule regulators. Several of these candidates were validated in both a human neuroglioma and a human neuroblastoma cell line. While these drugs lead to a rapid reduction in tau protein levels, a selective decrease in MAPT mRNA expression was also observed. Conclusion: These findings suggest that the identified compounds that reduce tau levels may act either through direct effects on the MAPT promoter itself or by altering a feedback transcriptional mechanism regulating MAPT transcription. This is particularly interesting in light of recent evidence suggesting that MAPT 5' UTR mutations in late-onset PD and PSP cases alter the expression of tau mRNA. In fact, one of the compounds we identified, rotenone, has been used extensively to model PD in rodents. These observations may provide key insights into the mechanism of tau turnover within the neuron while also providing the first evidence that selectively reducing tau protein levels may be possible using compounds that are PDA-approved for other uses.

UR - http://www.scopus.com/inward/record.url?scp=34248222543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248222543&partnerID=8YFLogxK

U2 - 10.1186/1750-1326-1-6

DO - 10.1186/1750-1326-1-6

M3 - Article

AN - SCOPUS:34248222543

VL - 1

JO - Molecular Neurodegeneration

JF - Molecular Neurodegeneration

SN - 1750-1326

IS - 1

M1 - 6

ER -